Schroder Investment Management Group Boosts Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Schroder Investment Management Group increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,046,400 shares of the company’s stock after buying an additional 478,971 shares during the period. Schroder Investment Management Group owned 0.50% of Teva Pharmaceutical Industries Limited worth $165,673,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Greylin Investment Mangement Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 36.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after acquiring an additional 79,300 shares during the last quarter. PGGM Investments increased its stake in Teva Pharmaceutical Industries Limited by 12.0% during the 2nd quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock worth $50,763,000 after purchasing an additional 163,292 shares in the last quarter. GAM Holding AG increased its stake in Teva Pharmaceutical Industries Limited by 23.2% during the 2nd quarter. GAM Holding AG now owns 41,900 shares of the company’s stock worth $1,392,000 after purchasing an additional 7,900 shares in the last quarter. Bank Hapoalim BM increased its stake in Teva Pharmaceutical Industries Limited by 9.2% during the 1st quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after purchasing an additional 980 shares in the last quarter. Finally, Analyst IMS Investment Management Services Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 8.4% during the 2nd quarter. Analyst IMS Investment Management Services Ltd. now owns 9,051 shares of the company’s stock worth $300,000 after purchasing an additional 700 shares in the last quarter. 56.87% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (TEVA) traded down 0.62% during midday trading on Wednesday, hitting $19.21. The stock had a trading volume of 12,386,843 shares. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $52.66. The firm’s 50-day moving average price is $20.22 and its 200 day moving average price is $28.82. The company’s market cap is $19.52 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.25 earnings per share. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.76%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.36%.

A number of research firms recently issued reports on TEVA. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price target for the company. in a research report on Thursday, June 22nd. BidaskClub downgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Gabelli reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Finally, Citigroup Inc. downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and cut their price objective for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Five analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $32.65.

ILLEGAL ACTIVITY WARNING: “Schroder Investment Management Group Boosts Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2017/09/13/teva-pharmaceutical-industries-limited-teva-shares-bought-by-schroder-investment-management-group.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply